Zelluna ASA Company Description

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway.

It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors.

The company was incorporated in 2016 and is headquartered in Oslo, Norway.

Zelluna ASA

Country	Norway
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	26
CEO	Namir Hassan

Contact Details

Address: Oslo Cancer Cluster Innovation Park Oslo, 0379 Norway
Phone	47 41 38 00 80
Website	zelluna.com

Stock Details

Ticker Symbol	ZLNA
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	NOK
ISIN Number	NO0013524942
SIC Code	2836

Key Executives

Name	Position
Namir Hassan Ph.D.	Chief Executive Officer
Geir Christian Melen MSc	Chief Financial Officer
Anders Holm Ph.D.	Chief Operating Officer and Head of Business Development
Emilie Gauthy Ph.D.	Chief Technology Officer
Luise Weigand Ph.D.	Chief Scientific Officer
Julia Ino Ph.D.	Head of Project Management
Oivind Foss Ph.D.	Head of Clinical Operations
Anders Tuv	Co-Founder and Chairman
Hans Ivar Robinson	Co-Founder and Non Executive Director
Jens Egil Torbjorn Bjorheim M.D., Ph.D.	Chief Medical Officer